Cosgrove Sara E
Division of Infectious Diseases, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9. doi: 10.1086/499406.
There is an association between the development of antimicrobial resistance in Staphylococcus aureus, enterococci, and gram-negative bacilli and increases in mortality, morbidity, length of hospitalization, and cost of health care. For many patients, inadequate or delayed therapy and severe underlying disease are primarily responsible for the adverse outcomes of infections caused by antimicrobial-resistant organisms. Patients with infections due to antimicrobial-resistant organisms have higher costs (approximately 6,000-30,000 dollars) than do patients with infections due to antimicrobial-susceptible organisms; the difference in cost is even greater when patients infected with antimicrobial-resistant organisms are compared with patients without infection. Strategies to prevent nosocomial emergence and spread of antimicrobial-resistant organisms are essential.
金黄色葡萄球菌、肠球菌和革兰氏阴性杆菌的耐药性发展与死亡率增加、发病率上升、住院时间延长以及医疗保健费用增加之间存在关联。对于许多患者来说,治疗不足或延迟以及严重的基础疾病是导致耐药菌感染不良后果的主要原因。与敏感菌感染的患者相比,耐药菌感染的患者费用更高(约6000 - 30000美元);将耐药菌感染患者与未感染患者相比,费用差异更大。预防医院内耐药菌的出现和传播的策略至关重要。